BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?

finance.yahoo.com · 2026-09-04

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]

TickrTrends take: BioMarin's decision to monetize a competing therapy through royalties rather than block it highlights a strategic shift in the pharmaceutical industry toward partnership-based revenue models. For ASND investors awaiting full valuation context, this development underscores how healthcare companies are increasingly generating returns from rival products, which could influence how competitors and investors evaluate ASND's own pipeline and licensing opportunities. The precedent set by larger players accepting royalty streams from alternatives may reshape expectations around ASND's potential partnerships and the valuation multiples applied to its revenue-generating assets.

Read the full story at finance.yahoo.com →